25 Years of Interferon-based Treatment of Chronic Hepatitis C: an Epoch Coming to an End

Overview

Journal Nat Rev Immunol

Specialty Allergy & Immunology

Date 2013 Jun 8

PMID 23743475

Citations 68

Authors

Markus H Heim

Affiliations

Soon will be listed here.

Abstract

Chronic hepatitis caused by infection with hepatitis C virus C (HCV) (therefore known as chronic hepatitis C (CHC)) is a leading cause of liver disease worldwide. For the past 25 years, recombinant interferon-α (IFNα) has been the main component of treatments for HCV infection. Treatment efficacy has shown a stepwise improvement following the pegylation of IFNα and its use in combination with other antiviral drugs. However, viral escape mechanisms, refractory IFNα signalling in the liver and substantial drug toxicity still limit the efficacy of this treatment. A new generation of HCV-specific antiviral drugs will probably improve response rates and might replace IFNs in CHC treatment in the next few years. This Timeline article summarizes the history of CHC treatment using recombinant IFNα with an emphasis on the mechanisms of action and the causes of non-response.

Citing Articles

The importance of IFNα2A (Roferon-A) in HSV-1 latency and T cell exhaustion in ocularly infected mice.

Wang S, Jaggi U, Katsumata M, Ghiasi H PLoS Pathog. 2024; 20(10):e1012612.

PMID: 39352890 PMC: 11469491. DOI: 10.1371/journal.ppat.1012612.

A Comparative Study of Human Pluripotent Stem Cell-Derived Macrophages in Modeling Viral Infections.

Zhang Y, Qiu H, Duan F, An H, Qiao H, Zhang X Viruses. 2024; 16(4).

PMID: 38675895 PMC: 11053470. DOI: 10.3390/v16040552.

Effects of HCV Clearance with Direct-Acting Antivirals (DAAs) on Liver Stiffness, Liver Fibrosis Stage and Metabolic/Cellular Parameters.

Ferreira J, Bicho M, Serejo F Viruses. 2024; 16(3).

PMID: 38543737 PMC: 10974411. DOI: 10.3390/v16030371.

Comparative outcomes of direct-acting antiviral treatment in patients with HIV-Hepatitis C co-infection: insights from a single center experience in Colombia.

Vergara-Samur H, Martinez-Vernaza S, De La Hoz A, Barahona-Correa J, Ortiz J, Gualtero-Trujillo S Infez Med. 2023; 31(3):374-383.

PMID: 37701377 PMC: 10495049. DOI: 10.53854/liim-3103-11.

Therapeutic strategies and promising vaccine for hepatitis C virus infection.

Adugna A Immun Inflamm Dis. 2023; 11(8):e977.

PMID: 37647422 PMC: 10461427. DOI: 10.1002/iid3.977.

References

Bigger C, Brasky K, Lanford R . DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol. 2001; 75(15):7059-66. PMC: 114434. DOI: 10.1128/JVI.75.15.7059-7066.2001. View

Poordad F, Dieterich D . Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat. 2012; 19(7):449-64. DOI: 10.1111/j.1365-2893.2012.01617.x. View

Kamal S, Fehr J, Roesler B, Peters T, Rasenack J . Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology. 2002; 123(4):1070-83. DOI: 10.1053/gast.2002.36045. View

Su A, Pezacki J, Wodicka L, Brideau A, Supekova L, Thimme R . Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A. 2002; 99(24):15669-74. PMC: 137774. DOI: 10.1073/pnas.202608199. View

Reichard O, Andersson J, Schvarcz R, Weiland O . Ribavirin treatment for chronic hepatitis C. Lancet. 1991; 337(8749):1058-61. DOI: 10.1016/0140-6736(91)91707-2. View

Shoukry N, Grakoui A, Houghton M, Chien D, Ghrayeb J, Reimann K . Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med. 2003; 197(12):1645-55. PMC: 2193956. DOI: 10.1084/jem.20030239. View

Feld J, Hoofnagle J . Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005; 436(7053):967-72. DOI: 10.1038/nature04082. View

Sarasin-Filipowicz M, Wang X, Yan M, Duong F, Poli V, Hilton D . Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol. 2009; 29(17):4841-51. PMC: 2725724. DOI: 10.1128/MCB.00224-09. View

Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C . A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med. 1995; 332(22):1457-62. DOI: 10.1056/NEJM199506013322201. View

10.

Hoofnagle J, Mullen K, Jones D, Rustgi V, Di Bisceglie A, Peters M . Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986; 315(25):1575-8. DOI: 10.1056/NEJM198612183152503. View

11.

Sarrazin C, Hezode C, Zeuzem S, Pawlotsky J . Antiviral strategies in hepatitis C virus infection. J Hepatol. 2012; 56 Suppl 1:S88-100. DOI: 10.1016/S0168-8278(12)60010-5. View

12.

Larner A, Chaudhuri A, Darnell Jr J . Transcriptional induction by interferon. New protein(s) determine the extent and length of the induction. J Biol Chem. 1986; 261(1):453-9. View

13.

Tester I, Smyk-Pearson S, Wang P, Wertheimer A, Yao E, Lewinsohn D . Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J Exp Med. 2005; 201(11):1725-31. PMC: 2213272. DOI: 10.1084/jem.20042284. View

14.

Schvarcz R, Yun Z, Sonnerborg A, Weiland O . Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Virol. 1995; 46(1):43-7. DOI: 10.1002/jmv.1890460110. View

15.

Paeshuyse J, Dallmeier K, Neyts J . Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Curr Opin Virol. 2012; 1(6):590-8. DOI: 10.1016/j.coviro.2011.10.030. View

16.

Sadler A, Williams B . Interferon-inducible antiviral effectors. Nat Rev Immunol. 2008; 8(7):559-68. PMC: 2522268. DOI: 10.1038/nri2314. View

17.

Schoggins J, Wilson S, Panis M, Murphy M, Jones C, Bieniasz P . A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011; 472(7344):481-5. PMC: 3409588. DOI: 10.1038/nature09907. View

18.

Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y . Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology. 2010; 139(2):499-509. DOI: 10.1053/j.gastro.2010.04.049. View

19.

Chen L, Borozan I, Feld J, Sun J, Tannis L, Coltescu C . Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology. 2005; 128(5):1437-44. DOI: 10.1053/j.gastro.2005.01.059. View

20.

Tellinghuisen T, Marcotrigiano J, Rice C . Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature. 2005; 435(7040):374-9. PMC: 1440517. DOI: 10.1038/nature03580. View